Journal
XENOBIOTICA
Volume 49, Issue 4, Pages 422-432Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/00498254.2018.1451667
Keywords
Doravirine; absorption; metabolism; mass balance; clinical trial; human immunodeficiency virus
Categories
Funding
- Merck Sharp & Dohme Corp., Merck & Co., Inc., Kenilworth, NJ, USA
Ask authors/readers for more resources
Absorption, distribution, metabolism and elimination of doravirine (MK-1439), a novel non-nucleoside reverse transcriptase inhibitor, were investigated. Two clinical trials were conducted in healthy subjects: an oral single dose [(14) C]doravirine (350 mg, similar to 200 mu Ci) trial (n = 6) and an intravenous (IV) single-dose doravirine (100 mu g) trial (n = 12). In vitro metabolism, protein binding, apparent permeability and P-glycoprotein (P-gp) transport studies were conducted to complement the clinical trials. Following oral [(14) C]doravirine administration, all of the administered dose was recovered. The absorbed dose was eliminated primarily via metabolism. An oxidative metabolite (M9) was the predominant metabolite in excreta and was the primary circulating metabolite (12.9% of circulating radioactivity). Following IV administration, doravirine clearance and volume of distribution were 3.73 L/h (95% confidence intervals (CI) 3.09, 4.49) and 60.5 L (95% CI 53.7, 68.4), respectively. In vitro, doravirine is not highly bound to plasma proteins (unbound fraction 0.24) and has good passive permeability. The metabolite M9 was generated by cytochrome P450 3A (CYP3A)4/5-mediated oxidation. Doravirine was a P-gp substrate but P-gp efflux is not expected to play a significant role in limiting doravirine absorption or to be involved in the elimination of doravirine. In conclusion, doravirine is a low clearance drug, primarily eliminated by CYP3A-mediated metabolism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available